Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on December 1, 2021. The filing reports a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and director compensation arrangements.
Material Changes
The primary material change is the appointment of Caroline S. Levy as a member of the Board of Directors, effective December 1, 2021. She will serve until the 2022 annual meeting of stockholders. Ms. Levy has been appointed to the Audit Committee and the Nominating and Corporate Governance Committee and has been determined to be an independent director.
Guidance, Outlook, and Compensation Details
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. The document details the following compensatory arrangements for Ms. Levy:
- Annual Retainer: $40,000 for Board service.
- Committee Fees: $10,000 for the Audit Committee and $5,000 for the Nominating and Corporate Governance Committee.
- Initial Stock Option Grant: 40,000 shares vesting in equal annual installments over three years.
- Annual Stock Option Grant: 20,000 shares granted at each annual meeting, vesting over one year.
- Exercise Price: Equal to the fair market value of common stock on the date of grant.
Investor Verification Checklist
- Verify the correct registrant name is ChromaDex Corporation (Ticker: CDXC), not Niagen Bioscience, Inc.
- Confirm Ms. Levy's independence status and committee assignments in subsequent proxy statements.
- Review the impact of the 40,000 initial option grant and future annual grants on potential dilution.
- Check the Company's most recent 10-Q or 10-K for actual financial performance metrics, as they are absent from this 8-K.